HR+/HER2- breast cancer
Oncology · 2005–2025
31decisions
12medicines
18carried consumer input
155individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ribociclib Adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), resected early breast cancer (eBC) at high… | Jul 2025 | Not recommended | input received Medical Oncology Group Australia · Rare Cancers Australia · Breast Cancer Network Australia · Inherited Cancers Australia |
| elacestrant Locally advanced or metastatic breast cancer in men and postmenopausal women with ER+/HER2- disease, an activating ESR1 variant, and disease progression… | Mar 2025 | Not recommended | 1 individuals Rare Cancers Australia · Breast Cancer Network Australia |
| ribociclib Adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) early breast cancer in combination with… | Nov 2024 | Recommended with restriction | input received Medical Oncology Group · Rare Cancers Australia · Inherited Cancers Australia · Breast Cancer Network Australia |
| capivasertib Treatment of locally advanced or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer with a… | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia · Breast Cancer Network Australia |
| sacituzumab govitecan Treatment of adult patients with unresectable locally advanced or metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)… | Jul 2023 | Recommended with restriction | input received Medical Oncology Group |
| abemaciclib Adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), lymph node positive, invasive, resected early… | Mar 2023 | Recommended with restriction | 2 individuals Medical Oncology Group · Breast Cancer Network Australia |
| abemaciclib Adjuvant treatment of hormone receptor positive, HER2-negative, lymph node positive, invasive, resected early breast cancer at high risk of disease recurrence,… | Nov 2023 | Recommended with restriction | input received Medical Oncology Group · Special Interest Group · Breast Cancer Network Australia · MOGA Breast Cancer Special Interest Group |
| sacituzumab govitecan Treatment of adult patients with unresectable locally advanced or metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)… | Nov 2023 | Not recommended | input received Consumer Group · Breast Cancer Network Australia |
| abemaciclib Adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), lymph node positive, invasive, resected,… | Mar 2022 | Not recommended | input received Breast Cancer Network Australia · Medical Oncology Group |
| palbociclib Treatment of patients with locally advanced (stage IIIB/IIIC) or metastatic (stage IV) hormone receptor positive (HR+), human epidermal growth factor receptor… | Mar 2022 | Recommended with restriction | unclear |
| palbociclib Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in… | Jul 2021 | Recommended with restriction | input received Rare Cancers Australia |
| abemaciclib Non-premenopausal patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) inoperable locally advanced or… | Mar 2021 | Recommended with restriction | 3 individuals Breast Cancer Network Australia · Medical Oncology Group |
| fulvestrant First-line and second-line endocrine-based treatment of non-premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor… | Jul 2020 | Recommended | unclear |
| ribociclib First- and second-line treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer… | Jul 2020 | Deferred | input received Breast Cancer Network Australia · Medical Oncology Group |
| ribociclib Treatment of non-premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) locally advanced or… | Nov 2020 | Recommended with restriction | 1 individuals |
| abemaciclib Initial endocrine-based treatment for non-premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative… | Mar 2019 | Recommended with restriction | 1 individuals Breast Cancer Network Australia |
| palbociclib Treatment of non-premenopausal patients with hormone receptor-positive, HER2-negative locally advanced inoperable breast cancer and metastatic breast cancer in… | Mar 2018 | Recommended | none received |
| ribociclib First-line endocrine-based treatment of non-premenopausal patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative… | Mar 2018 | Recommended | none received |
| ribociclib First-line endocrine-based treatment of non-premenopausal patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative… | Jul 2017 | Not recommended | 1 individuals |
| palbociclib Initial endocrine-based therapy in postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer, in combination with a… | Mar 2017 | Not recommended | 6 individuals Breast Cancer Network Australia |
| palbociclib Treatment of non-pre-menopausal patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative locally advanced… | Nov 2017 | Not recommended | 115 individuals |
| ribociclib First-line endocrine-based treatment of postmenopausal patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative… | Nov 2017 | Not recommended | 25 individuals |
| everolimus Treatment of post-menopausal women with hormone-receptor positive, HER2 negative advanced breast cancer in combination with exemestane after failure of… | Jul 2013 | Recommended | no section in document |
| everolimus Treatment, in combination with an aromatase inhibitor, of post-menopausal women with hormone-receptor positive, HER2 negative advanced breast cancer after… | Mar 2013 | Not recommended | unclear |
| Letrozole Treatment of hormone-dependent advanced and early breast cancer in post-menopausal women; extended adjuvant treatment of hormone-dependent early breast cancer… | Mar 2007 | Recommended with restriction | no section in document |
| exemestane treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years treatment with tamoxifen citrate | Jul 2006 | Recommended with restriction | no section in document |
| letrozole Treatment of hormone-dependent breast cancer in post-menopausal women. The PBAC recommended listing on a cost-minimisation basis with anastrozole in the early… | Jul 2006 | Recommended with restriction | no section in document |
| exemestane Sequential adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years treatment with tamoxifen citrate. | Jul 2006 | Recommended with restriction | no section in document |
| docetaxel adjuvant treatment of operable node-positive, oestrogen receptor positive breast cancer in combination with an anthracycline and cyclophosphamide | Mar 2006 | Recommended with restriction | no section in document |
| anastrozole Extension of restricted benefit listing to allow PBS-subsidised treatment of hormone-dependent early breast cancer in all post-menopausal women. | Jul 2005 | Recommended with restriction | no section in document |
| letrozole Treatment of early-stage hormone-dependent breast cancer in post-menopausal women who have completed no less than 4.5 years of standard adjuvant tamoxifen… | Nov 2005 | Not recommended | no section in document |
Who spoke
Breast Cancer Network Australia · Medical Oncology Group · Rare Cancers Australia · Inherited Cancers Australia · Special Interest Group · MOGA Breast Cancer Special Interest Group · Medical Oncology Group Australia · Consumer Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 18 of 22 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.